Combogesic Iv

Ensure correct prescribing, preparing, and administering to avoid dosing errors. Risk of acute liver failure (may result in liver transplant or death) associated with the use of doses higher than recommended or involving >1 acetaminophen-containing product. Alcoholism. Discontinue if signs/symptoms of liver disease develop, or if systemic manifestations occur. Hepatic or renal impairment: not recommended. Dehydration. Hypovolemia. Hyperkalemia. Advanced renal disease. Correct volume status prior to initiation. Risk for renal papillary necrosis, other renal injury with long-term NSAIDs therapy. Increased risk for serious cardiovascular events (including MI, stroke). Avoid in recent MI, severe heart failure; if necessary, monitor. Increased risk for serious GI adverse events (including inflammation, bleeding, ulceration, perforation). History of peptic ulcer disease and/or GI bleeding. Coagulation disorders. Hypertension; monitor BP closely. Preexisting asthma. May mask signs of infection or fever. Discontinue at 1^st sign of rash or any other hypersensitivity. Monitor CBCs, blood chemistry, hepatic, renal, and ocular function as clinically necessary. Elderly. Debilitated. Labor & delivery. May be associated with a reversible delay in ovulation in females of reproductive potential. Pregnancy (avoid during ≥30 weeks gestation): increased risk of premature closure of the fetal ductus arteriosus; (20–30 weeks gestation): may cause fetal renal dysfunction/oligohydramnios; if treatment needed, limit dose and duration of use. Nursing mothers.